2018, Number 2
Neoadjuvant chemotherapy with methotrexate, vinblastine, adriamycin and cisplatin in the treatment of unresectable bladder cancer
Sierra PL, Morales YRA, Ibáñez CE
Full text
Language: Spanish
References: 0
Page: 165-168
PDF size: 283.32 Kb.
ABSTRACT
A descriptive cross-sectional study was made with the objective of characterizing patients who received a neoadjuvant chemotherapy scheme with methotrexate, vinblastine, adriamycin and cisplatin for unresectable bladder cancer. The sample included 47 patients seen at “Dr. Celestino Hernández Robau” University Hospital from September, 2010 to December, 2014 with the anatomopathological diagnosis of unresectable bladder cancer in clinical stage T3b-T4a-b N0, M0. The 72.3 % of patients responded favourably to this therapy. Patients who responded worse were those diagnosed with a squamous cell carcinoma (4.3 %); the best objective antitumor response occurred in clinical stage T3 b (44.6 %). Most of the patients responded favourably to the first lineneoadjuvant therapy used for the treatment of unresectable bladder cancer. Prognosis factors related to treatment response were tumor size and histology.